Pulmonary Drugs Market (Drug Class - Long-acting Beta2-agonists (LABA), Short-acting Beta2-agonists (SABA), Anticholinergics, Inhaled Corticosteroids (ICS), Antihistamines, Vasodilators, and Other Drug Class; Application - Pulmonary Arterial Hypertension, Cystic Fibrosis, Asthma & COPD, and Other Applications; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, and Other Distribution Channel): Global Industry Analysis, Trends, Size, Share and Forecasts to 2025

  • Published : April, 2019

  • Rep Id : HC0481

  • Category : Healthcare & Medical Devices

  • Status : Published

A recent report published by Infinium Global Research on pulmonary drugs market provides in-depth analysis of segments and sub-segments in the global as well as regional pulmonary drugs market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional pulmonary drugs market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of the global pulmonary drugs market. According to the report, the global pulmonary drugs market is projected to grow at a CAGR of 4.3% over the forecast period of 2019-2025.


Market Insight

Pulmonary drugs are used in the treatment of asthma, chronic obstructive pulmonary disease (COPD), pneumonia, and other pulmonary disorder. Pulmonary drugs help to provide medications for pulmonary disorders. In pulmonary drug delivery inhalation of the drug, the formulation is through the mouth and the main purpose of this drug delivery route is deposition of the inhaled pharmacological agent in lower airways.


Growing prevalence of chronic obstructive pulmonary disease (COPD) drives the growth of pulmonary drugs market. Worldwide, more than 300 million people suffer from asthma or Chronic obstructive pulmonary disorder (COPD). Asthma is the most common chronic disease worldwide mainly its affection is increasing in children. Further, pulmonary drug delivery technologies are advancing very rapidly owing to increasing adoption of the pulmonary route as an alternative to oral and parenteral delivery methods in the pharmaceutical industry. Numbers of new pulmonary drug candidates entering the drug development pipeline are increasing and these advancements in pulmonary drug delivery technologies are attracting new players and new investment. These factors boost the growth of pulmonary drugs market. Furthermore, the rising incidence of lung diseases and chronic obstructive pulmonary diseases owing to the increase in tobacco smoking contribute to the growth of pulmonary drugs market. However, less awareness regarding pulmonary drugs delivery may hamper the growth of pulmonary drugs market.


Among the geographies, North America dominated the pulmonary drugs market. According to the global asthma network, asthma affects around 339 million people in all regions of the world. Among these, 22 million persons affected by asthma in the United States. Increasing geriatric population in the United States coupled with increasing demand for pulmonary drugs that in turn fuel the growth of pulmonary drugs market in the North America region. The United Nations (UN) has included asthma in all its NCD deliberations. Growing prevalence of asthma, government initiatives for the reduction in the treatment costs, these factors contribute to the growth of pulmonary drugs market in the North America region. Furthermore, in Asia Pacific, increasing expenditure on healthcare fuels the growth of pulmonary drugs market. Ongoing initiatives and product guidance from European Medicines Agency, International Standards Organization standards for drug delivery devices, draft pharmacopeia monographs of the US FDA to boost the growth of pulmonary drugs market in several regions.

Global Pulmonary Drugs Market


Segment Covered

The report on global pulmonary drugs market covers segments such as drug class, application, and distribution channel. On the basis of drug class, the sub-markets include long-acting beta2-agonists (LABA), short-acting beta2-agonists (SABA), anticholinergics, inhaled corticosteroids (ICS), antihistamines, vasodilators, and other drug class. On the basis of application, the sub-markets include pulmonary arterial hypertension, cystic fibrosis, asthma & COPD, and other applications. On the basis of distribution channel, the sub-markets include hospital pharmacies, retail pharmacies, drug stores, and other distribution channel.


Companies Profiled:

The report provides profiles of the companies in the market such as Sunovion Pharmaceuticals Inc., AstraZeneca, Novartis AG, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Merck Sharp & Dohme Corp, Boehringer Ingelheim International GmbH., Actelion Pharmaceuticals Ltd, and Others.


Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of pulmonary drugs market. Moreover, the study highlights current market trends and provides forecast from 2019-2025. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.

Other Reports in This Category
24 hour delivery through email
9923950043 Monday to Frieday 9am-7pm
looking for discount